Study of Lotilaner Ophthalmic Gel in Patients With Ocular Rosacea (KORE)

Enrolling by invitation · Phase 2

Conditions studied: Ocular Rosacea

In brief

To evaluate lotilaner treatment in patients with ocular rosacea.

Key facts

Study ID

NCT07443202

Run by

Tarsus Pharmaceuticals, Inc.

People needed

155

Starts

2025-12-05

Expected to finish

2027-12-31

Last updated by the study team

2026-03-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 18 years of age or older at the time of consent.
• Has moderate to severe ocular rosacea
• Use of acceptable methods of contraception
• Are willing to sign the informed consent form and is deemed capable of complying with the requirements of the study protocol

You may not qualify if…

• Patient taking a topical or other therapy which may affect the patients rosacea
• Actively managed glaucoma or active ocular infection or ocular systemic disease
• Have hypersensitivity to lotilaner or any of the formulation components
• Are currently enrolled in an investigational drug or device study
• Are currently pregnant or lactating or planning to become pregnant during the study

Where it is running

• Site — Houston, Texas, United States
• Site — Lynchburg, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.